Search for DSIP in a clinical trial registry and you will find something striking: essentially nothing. That absence is itself the story of the DSIP clinical trial landscape — a compound with a fifty-year published literature and no registered trials to its name. This article maps that landscape factually: what ClinicalTrials.gov returns for DSIP today, why the registry is empty, where the historical human research actually lives, and how this picture compares with a peptide that did travel the full clinical route. No invented trial identifiers, no registry entries that do not exist — just the DSIP clinical trial landscape as the data shows it.
Research-use-only disclaimer: DSIP is not an FDA-approved drug and is not a medicine. It is handled as a research compound for laboratory and scientific investigation only. This article describes clinical trial registry data for educational purposes. It contains no dosage information, no usage instructions, and no medical advice, and nothing here recommends human use of any compound.
The DSIP Clinical Trial Landscape in One Snapshot
The fastest way to grasp the DSIP clinical trial landscape is to look at the numbers as the registry reports them. A direct query of the ClinicalTrials.gov public API — the same database researchers use to find registered trials worldwide — returns the following for DSIP-related terms:
0 — registered studies matching “DSIP” on ClinicalTrials.gov
0 — registered studies matching “deltaran” (the DSIP-containing preparation studied in Russian research)
~86 — records returned for the phrase “delta sleep-inducing peptide,” none of them DSIP trials
10 — registered studies matching “bremelanotide,” shown here only as a contrast case
Those four figures are the entire DSIP clinical trial landscape on the world’s largest trial registry: two exact-match queries with zero results, one phrase query that matches only the individual words, and a comparator showing the registry works fine for peptides that actually went through modern clinical development. The rest of this article explains why the zeros are real, what they mean, and where DSIP’s human research actually resides.
How these numbers were obtained: The figures above come from the ClinicalTrials.gov API v2, queried for the exact terms shown. Registry data changes as new studies are registered, so a researcher repeating these searches in the future should expect the same method — query the exact compound name first, then check phrase variants — rather than the same numbers.
Why the DSIP Clinical Trial Landscape Is Empty
An empty registry result can mean several things: the compound was never tested in humans, the trials were never registered, or development stopped before registration became standard. For DSIP, the answer is a combination of the second and third — and the timeline makes it clear.
DSIP’s human research predates the registry
ClinicalTrials.gov was launched in 2000, with mandatory registration of most trials arriving later still. The DSIP clinical trial landscape that matters — the human studies of the 1980s and early 1990s — happened entirely before the registry existed. The Schneider-Helmert sleep studies, the Larbig chronic-pain pilot, the Dick withdrawal-syndrome trial: all were published in the 1980s, all were small by modern standards, and none could have been registered because there was no registry to register them in. The DSIP clinical trial landscape is empty partly because the compound’s clinical era ended before the era of trial registration began.
Pharmaceutical development stopped in the early 2000s
The second reason is simpler: nobody took DSIP into modern clinical development. The human trials that tested the peptide most carefully found weak effects and said so — the double-blind insomnia investigators concluded short-term treatment was not likely to be of major therapeutic benefit — and pharmaceutical development stopped in the early 2000s. DSIP was never approved anywhere for any indication. No development program means no phase 1, 2, or 3 trials to register, which is why the DSIP clinical trial landscape shows zero where a developed compound would show dozens.

The Russian research tradition worked outside the registry
A third factor: the research tradition that kept DSIP alive longest — Russian work on the DSIP-containing preparation Deltaran, including aging-biomarker studies in mice and antistress research — operated largely outside Western trial registries. A ClinicalTrials.gov query for “deltaran” returns zero studies, which reflects where that work was published and registered (in Russian journals and domestic systems), not whether the work happened. The DSIP clinical trial landscape as seen from Bethesda is therefore an incomplete map of global DSIP research — accurate for what it covers, silent on what it does not.
An important distinction: “No registered trials” is not the same as “no human research.” The DSIP clinical trial landscape on ClinicalTrials.gov is empty, but the published literature contains small human studies from the 1980s and early 1990s. Registry absence tells you about modern clinical development; the journals tell you about the historical human work. Both are needed for the full picture.
Reading the Registry: A Checklist for DSIP Researchers
The DSIP clinical trial landscape is a good case study in how to read trial registries critically. Use this checklist when you search any legacy compound:
- Query the exact name first. “DSIP” returns zero on ClinicalTrials.gov — the cleanest possible answer. Exact-match queries are the most reliable signal in any registry search.
- Check common variants and related preparations. “Deltaran,” the DSIP-containing preparation from Russian research, also returns zero. Variant names can hide in registries; for DSIP they do not.
- Distrust phrase queries without inspection. “Delta sleep-inducing peptide” returns around 86 records — but spot-checking shows trials on unrelated topics that merely match the individual words (sleep, peptide). A hit count is not a result count until you read the titles.
- Check whether the registry postdates the research. ClinicalTrials.gov launched in 2000; DSIP’s human trials were published in the 1980s. An empty registry for a pre-2000 compound is expected, not suspicious.
- Look for a comparator. “Bremelanotide” returns 10 registered studies, including completed phase 3 trials. The contrast confirms the method works — the DSIP clinical trial landscape is empty because DSIP has no modern trials, not because the search failed.
- Remember what registries do not cover. Pre-2000 studies, Russian domestic research, and investigator work published only in journals will not appear on ClinicalTrials.gov. The registry is a map of modern regulated development, not of all human research.
DSIP vs. Bremelanotide: Two Peptides, Two Registry Stories
The contrast between DSIP and bremelanotide (PT-141) is the clearest illustration of what the DSIP clinical trial landscape means. Both are synthetic research peptides with decades of history. One traveled the full modern clinical route; the other did not. The registry shows the difference plainly.
| Registry feature | DSIP | Bremelanotide (PT-141) |
|---|---|---|
| Exact-name query results | 0 studies | 10 studies |
| Phase 3 trials registered | None | Completed phase 3 trials in premenopausal women with HSDD, plus a phase 3 bridging trial |
| Regulatory outcome | Never approved anywhere | FDA-approved June 2019 as Vyleesi for HSDD in premenopausal women |
| Human research era | 1980s–early 1990s (pre-registry) | 2000s–2010s (registry era) |
| Why the registry looks this way | Development stopped before/without modern trials | Full modern development program with registered trials |
The table is not a comparison of the compounds’ merits — it is a comparison of their development histories as the registry records them. The DSIP clinical trial landscape is empty because DSIP’s story unfolded before registries mattered and ended before modern development began. Bremelanotide’s registry presence reflects a development program that ran straight through the registry era to FDA approval. For background on that program, see our PT-141 Research Timeline and the published history of bremelanotide.

Where DSIP’s Human Research Actually Lives
If the DSIP clinical trial landscape on ClinicalTrials.gov is empty, where should a researcher look? The answer is the journals — specifically, the small human studies of the 1980s and early 1990s that constitute the entire clinical record:
- Sleep behavior studies — Schneider-Helmert and colleagues published the core human sleep work: acute and delayed effects on human sleep behavior (1981), 24-hour sleep-wake behavior in severe chronic insomnia (1987), and a closely monitored single case of phase-shifted insomnia (1987). All used slow intravenous infusion; all were small.
- Chronic pain pilot — Larbig and colleagues (1984) tested DSIP in patients with chronic, pronounced pain episodes, extending the animal antinociception findings into a clinical pilot.
- Withdrawal syndrome trial — Dick and colleagues (1983) tested DSIP in opiate and alcohol withdrawal, reporting symptom alleviation in large majorities of small patient groups — striking as reported, never replicated at scale, and predating modern trial standards.
- Endogenous presence — Graf, Hunter and Kastin (1984) reported DSIP-like immunoreactive material in human milk, the key human evidence that something DSIP-like occurs naturally.
Every one of these predates ClinicalTrials.gov. None appears in the registry. All are indexed on PubMed under “delta sleep-inducing peptide” or “DSIP.” The DSIP clinical trial landscape is therefore a two-part picture: an empty modern registry and a small, aging journal literature — and a researcher who checks only one will misunderstand the compound.
What “no registered trials” does not mean: It does not mean DSIP was never studied in humans (it was, in small 1980s trials). It does not mean the compound is proven ineffective (the trials were too small for that conclusion). And it does not mean new research is impossible — it means no modern regulated development program exists, which is itself a significant fact about the DSIP clinical trial landscape.
The Regulatory Footnote
One more factual element of the DSIP clinical trial landscape: DSIP has never been approved by any major regulatory body for any indication, and pharmaceutical development stopped in the early 2000s. It appears on the FDA’s category 2 bulk substances list — a regulatory classification concerning bulk drug substances, not an approval. For researchers, the practical meaning is straightforward: DSIP exists in the literature and in the laboratory, not in the clinic, and the registry data reflects exactly that status. The FDA’s public resources explain what approval status and bulk-substance listings mean.

Key Takeaways: DSIP Clinical Trial Landscape
1. The registry is genuinely empty. ClinicalTrials.gov returns zero studies for “DSIP” and zero for “deltaran.” The phrase query returns only word-match noise. No NCT numbers exist for DSIP because no DSIP trials were ever registered.
2. The emptiness has three causes. DSIP’s human research predates the registry (launched 2000), pharmaceutical development stopped in the early 2000s before modern trials could happen, and the Russian research tradition worked outside Western registries.
3. Empty registry ≠ no human research. Small human trials from the 1980s — sleep, pain, withdrawal — exist in the journals and are indexed on PubMed. The DSIP clinical trial landscape is an empty modern registry plus an aging journal literature.
4. The bremelanotide contrast validates the method. Ten registered bremelanotide studies show the registry works; DSIP’s zero is a real finding about its development history, not a search failure.
Research framing only — a factual summary of registry data, not a recommendation regarding any compound.
DSIP Clinical Trial Landscape: Final Research Notes
The DSIP clinical trial landscape is unusual: a compound famous enough to have a Wikipedia page and a fifty-year literature, with a trial-registry footprint of zero. That fact is worth stating plainly, because it corrects two opposite errors — assuming the literature implies a clinical program (it does not), and assuming the empty registry implies no human research ever happened (it did, in the 1980s).
For researchers, the practical guidance is simple. Search the registry by exact compound name, inspect phrase-query hits before counting them, and remember that ClinicalTrials.gov maps modern regulated development — which DSIP never had. The historical human work lives in the journals, indexed on PubMed, and the honest summary of that work — small trials, mixed signals, development long stopped — is the real DSIP clinical trial landscape.
Researchers studying related compounds can browse our research overviews — our DSIP Explained for Beginners primer, the DSIP Key Research Findings roundup, and our DSIP 5mg research listing, with lot documentation in the COA Library. Trial registry data itself is public at ClinicalTrials.gov, an NIH service.

DSIP Clinical Trial Landscape: Frequently Asked Questions
Quick answers to the questions researchers ask most about DSIP and trial registries — all in research framing.
Are there any DSIP trials registered on ClinicalTrials.gov?
No. A direct query of the ClinicalTrials.gov API for “DSIP” returns zero studies, and a query for “deltaran” — the DSIP-containing preparation from Russian research — also returns zero. The DSIP clinical trial landscape on the world’s largest trial registry is empty: no registered trials, and therefore no NCT numbers, exist for DSIP.
Why does a phrase search for “delta sleep-inducing peptide” return results?
Because the registry matches the individual words, not the compound. The phrase query returns around 86 records, but spot-checking shows trials on unrelated topics that merely contain words like “sleep” or “peptide.” In the DSIP clinical trial landscape, a hit count is not a result count until you read the titles — and none of them are DSIP trials.
Does an empty registry mean DSIP was never tested in humans?
No. The DSIP clinical trial landscape on ClinicalTrials.gov is empty, but small human studies were published in the 1980s and early 1990s — on sleep behavior, chronic pain, and withdrawal syndrome — before the registry existed. Registry absence reflects the lack of modern clinical development, not the absence of all human research.
How does DSIP’s registry picture compare with bremelanotide’s?
Sharply. “Bremelanotide” returns 10 registered studies on ClinicalTrials.gov, including completed phase 3 trials, reflecting a full modern development program that ended in FDA approval in 2019. The DSIP clinical trial landscape shows zero because DSIP’s development stopped in the early 2000s without modern trials — the contrast confirms the search method works.
Is DSIP approved by the FDA or any other regulator?
No. DSIP has never been approved anywhere for any indication, and pharmaceutical development stopped in the early 2000s. It appears on the FDA’s category 2 bulk substances list, which is a classification of bulk drug substances — not an approval. This regulatory status is consistent with the empty DSIP clinical trial landscape.
Where should researchers look for DSIP’s actual human data?
In the journals, not the registry. The human studies — Schneider-Helmert’s sleep work, Larbig’s pain pilot, Dick’s withdrawal trial, Graf’s human-milk findings — are indexed on PubMed under “delta sleep-inducing peptide” or “DSIP.” Registry data itself is public at ClinicalTrials.gov. Research compounds are supplied for laboratory use only, as with our DSIP 5mg research listing, with lot documentation in the COA Library.

